Tweet
Analysts expect DelMar Pharmaceuticals Inc (NASDAQ:DMPI) to announce earnings per share of ($0.11) for the current fiscal quarter, according to Zacks . Zero analysts have issued estimates for DelMar Pharmaceuticals' earnings. DelMar Pharmaceuticals posted earnings of ($0.20) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 45%. The company is expected to issue its next quarterly earnings results on Wednesday, September 26th.
On average, analysts expect that DelMar Pharmaceuticals will report full year earnings of ($0.54) per share for the current financial year. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.30) per share. Zacks Investment Research's earnings per share calculations are a mean average based on a survey of research firms that follow DelMar Pharmaceuticals. Get DelMar Pharmaceuticals alerts:
DelMar Pharmaceuticals (NASDAQ:DMPI) last released its earnings results on Tuesday, May 15th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by ($0.03). DMPI has been the subject of several recent analyst reports. HC Wainwright set a $12.00 target price on shares of DelMar Pharmaceuticals and gave the stock a "buy" rating in a research note on Wednesday, May 23rd. ValuEngine upgraded shares of DelMar Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 2nd.
DMPI stock opened at $0.49 on Tuesday. DelMar Pharmaceuticals has a one year low of $0.33 and a one year high of $2.29. The firm has a market capitalization of $11.30 million, a PE ratio of -0.66 and a beta of 1.74.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter 